Skip to main content
Fig. 2 | BMC Rheumatology

Fig. 2

From: Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy

Fig. 2

Cancer response to ICI therapy. Time to cancer outcomes from start of ICI therapy and onset of immune events (flare of underlying rheumatologic disease and/or irAE). Blue indicates favorable cancer outcomes defined as partial remission or stable disease and was censored on the date of their last documented cancer response assessment after the start of ICI therapy. Red indicates unfavorable cancer outcomes defined as mixed response, progression, or death and time to event of interest is reported in the number of days determined from start of ICI therapy. Cancer outcome abbreviations: CR = complete remission, PR = partial remission, NP = no progression, M = mixed response, PG = progressed on treatment, PGO = progressed off treatment, D = death

Back to article page